Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

NADPH oxidase regulates efficacy of vaccination in aspergillosis.

Deepe GS Jr.

J Clin Invest. 2012 May;122(5):1608-11. doi: 10.1172/JCI63417. Epub 2012 Apr 23.

2.

CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease.

De Luca A, Iannitti RG, Bozza S, Beau R, Casagrande A, D'Angelo C, Moretti S, Cunha C, Giovannini G, Massi-Benedetti C, Carvalho A, Boon L, Latgé JP, Romani L.

J Clin Invest. 2012 May;122(5):1816-31. doi: 10.1172/JCI60862. Epub 2012 Apr 23.

3.

Vaccinate against aspergillosis! A call to arms of the immune system.

Stevens DA.

Clin Infect Dis. 2004 Apr 15;38(8):1131-6. Epub 2004 Apr 5.

PMID:
15095219
4.

T cell vaccination in mice with invasive pulmonary aspergillosis.

Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L.

J Immunol. 2000 Jul 1;165(1):381-8.

5.

Whole glucan particles as a vaccine against murine aspergillosis.

Clemons KV, Danielson ME, Michel KS, Liu M, Ottoson NC, Leonardo SM, Martinez M, Chen V, Antonysamy MA, Stevens DA.

J Med Microbiol. 2014 Dec;63(Pt 12):1750-9. doi: 10.1099/jmm.0.079681-0. Epub 2014 Oct 6.

PMID:
25288643
6.

Impaired macrophage function following bacterial stimulation in chronic granulomatous disease.

Rahman FZ, Hayee B, Chee R, Segal AW, Smith AM.

Immunology. 2009 Oct;128(2):253-9. doi: 10.1111/j.1365-2567.2009.03112.x.

7.

Vaccination approaches against opportunistic fungal infections caused by Aspergillus fumigatus.

Reichard U, Herrmann S, Asif AR.

Curr Protein Pept Sci. 2014;15(5):424-9. Review.

8.

Aspergillus nidulans and chronic granulomatous disease: a unique host-pathogen interaction.

Henriet SS, Verweij PE, Warris A.

J Infect Dis. 2012 Oct 1;206(7):1128-37. doi: 10.1093/infdis/jis473. Epub 2012 Jul 24. Review.

PMID:
22829648
9.

Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients.

Potenza L, Vallerini D, Barozzi P, Riva G, Forghieri F, Beauvais A, Beau R, Candoni A, Maertens J, Rossi G, Morselli M, Zanetti E, Quadrelli C, Codeluppi M, Guaraldi G, Pagano L, Caira M, Del Giovane C, Maccaferri M, Stefani A, Morandi U, Tazzioli G, Girardis M, Delia M, Specchia G, Longo G, Marasca R, Narni F, Merli F, Imovilli A, Apolone G, Carvalho A, Comoli P, Romani L, Latgè JP, Luppi M.

PLoS One. 2013 Sep 4;8(9):e74326. doi: 10.1371/journal.pone.0074326. eCollection 2013.

10.

Feasibility and prospects for a vaccine to prevent cryptococcosis.

Casadevall A, Pirofski LA.

Med Mycol. 2005 Dec;43(8):667-80. Review.

PMID:
16422296
11.

Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent.

Bianchi M, Niemiec MJ, Siler U, Urban CF, Reichenbach J.

J Allergy Clin Immunol. 2011 May;127(5):1243-52.e7. doi: 10.1016/j.jaci.2011.01.021. Epub 2011 Mar 3.

PMID:
21376380
12.

Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease.

Henriet SS, Jans J, Simonetti E, Kwon-Chung KJ, Rijs AJ, Hermans PW, Holland SM, de Jonge MI, Warris A.

J Infect Dis. 2013 Jun 15;207(12):1932-9. doi: 10.1093/infdis/jit103. Epub 2013 Mar 12.

PMID:
23482646
13.

Invasive aspergillosis in chronic granulomatous disease.

Segal BH, Romani LR.

Med Mycol. 2009;47 Suppl 1:S282-90. doi: 10.1080/13693780902736620. Epub 2009 Mar 18. Review.

PMID:
19296367
14.

Prospects of vaccines for invasive aspergillosis.

Feldmesser M.

Med Mycol. 2005 Nov;43(7):571-87. Review.

PMID:
16396243
15.

Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH.

Antimicrob Agents Chemother. 2006 Feb;50(2):422-7.

16.

Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous disease.

Petersen JE, Hiran TS, Goebel WS, Johnson C, Murphy RC, Azmi FH, Hood AF, Travers JB, Dinauer MC.

J Invest Dermatol. 2002 Mar;118(3):424-9.

17.

Evaluation of immunogenicity and protective efficacy of a Microsporum canis metalloprotease subunit vaccine in guinea pigs.

Vermout SM, Brouta FD, Descamps FF, Losson BJ, Mignon BR.

FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):75-80.

18.

Immunity to Aspergillus in patients with chronic granulomatous disease.

Greenberg D, Ammann AJ, Wara DW, Kaltreider HB.

J Pediatr. 1977 Apr;90(4):601-3. No abstract available.

PMID:
320301
19.

Phagocyte NADPH oxidase and specific immunity.

Cachat J, Deffert C, Hugues S, Krause KH.

Clin Sci (Lond). 2015 May 1;128(10):635-48. doi: 10.1042/CS20140635. Review.

PMID:
25760962
20.

Update on chronic granulomatous disease: the concept of the near-normal host.

Ezekowitz RA.

Curr Clin Top Infect Dis. 2000;20:325-34. Review. No abstract available.

PMID:
10943531

Supplemental Content

Support Center